Julia Dorna-Eckl

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications

Baseline EPOS 2020 eligibility and real-world outcomes of dupilumab in CRSwNP: a longitudinal cohort study.

Baseline EPOS 2020 eligibility and real-world outcomes of dupilumab in CRSwNP: a longitudinal cohort study.

Journal: Rhinology
Published: August 11, 2026

Does Prior Sinus Surgery Influence Dupilumab Treatment Response in CRSwNP?

Does Prior Sinus Surgery Influence Dupilumab Treatment Response in CRSwNP?

Journal: Clinical and experimental otorhinolaryngology
Published: June 18, 2026

Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1.

Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1.

Journal: Frontiers in immunology
Published: April 24, 2026

Long-term dupilumab therapy reduces concomitant medication use in patients with CRSwNP.

Long-term dupilumab therapy reduces concomitant medication use in patients with CRSwNP.

Journal: Rhinology
Published: March 19, 2026

Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR.

Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR.

Journal: Rhinology
Published: February 17, 2026

Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR.

Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR.

Journal: Rhinology
Published: February 17, 2026

Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes.

Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes.

Journal: International forum of allergy & rhinology
Published: November 22, 2025

Kinetics of Antibody Responses and Effector Cell Sensitivity After High Dose Birch Extract Nasal Challenge.

Kinetics of Antibody Responses and Effector Cell Sensitivity After High Dose Birch Extract Nasal Challenge.

Journal: Allergy
Published: October 23, 2025

Indication for biologic treatment in a real-world cohort of chronic rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR).

Indication for biologic treatment in a real-world cohort of chronic rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR).

Journal: The World Allergy Organization journal
Published: September 29, 2025

Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR).

Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR).

Journal: Rhinology
Published: September 10, 2025

Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR).

Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR).

Journal: Clinical and translational allergy
Published: September 09, 2025

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract-the B Cell Side.

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract-the B Cell Side.

Journal: Allergy
Published: July 30, 2025
Showing 1-12 of 79

Last Updated: 09/26/2026